Skip to main content
SpringerLink
Log in

Neurological Manifestations in Fabry Disease

  • Chapter
  • First Online:
Fabry Disease

Abstract

Neurological manifestations of Fabry disease occur in both the peripheral nervous system (PNS) and central nervous system (CNS), with globotriaosylceramide (Gb3) accumulation in neurons, Schwann cells and dorsal root ganglia. The abnormal Gb3 accumulation in neurons appears to have little clinical consequence on the natural history of Fabry disease. The vascular change in Fabry disease is considered to be responsible for increased regional cerebral blood flow (rCBF) documented in PET scans, especially in the posterior circulation. There is clear evidence for an increased number of lacunar infarctions, predominantly periventricular, as well as small cortical infarcts – in females as well as in males. However, the pathogenesis of Fabry vasculopathy remains mostly unclear, but is based on the combination of endothelial dysfunction and abnormal function control of the vessels. It is widely accepted that cerebral hyperperfusion, predominantly in the posterior cerebral circulation is an important cornerstone in the pathophysiology of stroke in Fabry disease. Additionally, inflammation seems to have an influence on the progress of the vasculopathy in Fabry disease. The majority of Fabry stroke patients both in the hemizygote and the heterozygote groups present symptoms and clinical signs of vertebrobasilar ischemia. Consequently, vertigo/dizziness, diplopia, dysarthria, nystagmus, ataxia are the most frequent symptoms in stroke patients with Fabry.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grewal RP (1994) Stroke in Fabry’s disease. J Neurol 241:153–156

    Article  PubMed  CAS  Google Scholar 

  2. Rolfs A, Böttcher T, Zschiesche M et al (2005) High prevalence of Fabry disease in young stroke patients. Lancet 366:1794–1796

    Article  PubMed  Google Scholar 

  3. Schiffman R, Ries M (2005) Fabry’s disease—an important risk factor for stroke. Lancet 366:1754–1756

    Article  Google Scholar 

  4. Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746–1749

    Article  PubMed  CAS  Google Scholar 

  5. Fellgiebel A, Albrecht J, Dellani PR et al (2007) Quantification of brain tissue alterations in Fabry disease using diffusion tensor imaging. Acta Paediatr Suppl 96:33–36

    Article  PubMed  Google Scholar 

  6. Takanashi J, Barkovich AJ, Dillon WP et al (2003) T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 24:916–921

    PubMed  Google Scholar 

  7. Moore DF, Ye F, Schiffmann R, Butman JA (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 24:1096–1101

    PubMed  Google Scholar 

  8. Burlina AP, Manara R, Caillaud C et al (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738–744

    Article  PubMed  Google Scholar 

  9. Hilz MJ, Kolodny EH, Brys M et al (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251:564–570

    Article  PubMed  Google Scholar 

  10. Moore DF, Scott LTC, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Reversal by enzyme replacement therapy. Circulation 104:1506–1512

    Article  PubMed  CAS  Google Scholar 

  11. Moore D, Kaneski CR, Askari H et al (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258–263

    Article  PubMed  Google Scholar 

  12. Altarescu G, Moore DF, Pursley R et al (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32:1559–1562

    Article  PubMed  CAS  Google Scholar 

  13. Fellgiebel A, Muller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5:791–795

    Article  PubMed  Google Scholar 

  14. Eyskens FJ, De Deyn PP (2009) Belgian Fabry stroke study (BEFAS): a national, multicentre, prospective study on the prevalence of Fabry disease in young stroke patients with stroke. Mol Genet Metabol 98:1–2

    Article  Google Scholar 

  15. Sims K, Politei J, Banikazemi M et al (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40(3):788–794

    Article  PubMed  Google Scholar 

  16. Moore DF, Herscovitch P, Schiffmann R (2001) Selective arterial distribution of cerebral hyper-perfusion in Fabry disease. J Neuroimaging 11:303–307

    Article  PubMed  CAS  Google Scholar 

  17. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40:8–17

    Article  PubMed  CAS  Google Scholar 

  18. Taglianini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A (1982) Anderson-Fabry’s disease: neuropathological and neurochemical investigation. Acta Neuropathol (Berl) 56:93–98

    Article  Google Scholar 

  19. Kaye EM, Kolodny EH, Logigian EL et al (1988) Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol 23:505–509

    Article  PubMed  CAS  Google Scholar 

  20. Gavazzi C, Borsini W, Guerrini L et al (2006) Subcortical damage and cortical functional changes in men and women with Fabry disease: a multifaceted MR study. Radiology 241:492–500

    Article  PubMed  Google Scholar 

  21. Resta M, Gentile A, Cuonzo FD (1984) Clinical-angiographic correlations in 132 patients with megadolichovertebrobasilar anomaly. Neuroradiology 26:213–216

    Article  PubMed  CAS  Google Scholar 

  22. Yu Y, Mosely IF, Pullicino P et al (1982) The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry 45:29–36

    Article  PubMed  CAS  Google Scholar 

  23. Fellgiebel A, Keller I, Marin D et al (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72(1):63–68

    Article  PubMed  CAS  Google Scholar 

  24. DeGraba T, Azhar S, Dignat-George F et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47:229–233

    Article  PubMed  CAS  Google Scholar 

  25. Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Europ J Clin Invest 34:236–242

    Article  PubMed  CAS  Google Scholar 

  26. Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46(8):548–552

    Article  PubMed  CAS  Google Scholar 

  27. Leech N, Johnson K (2003) Enzyme replacement treatment in “cerebrovascular” Fabry disease – when is it too late? The 4th European round table on Fabry disease. Expectations of enzyme replacement therapy, Oct 17–18, 2003, Munich, Germany

    Google Scholar 

  28. Suresh S, Thompson L, Kenny M et al (2003) The effect of enzyme replacement therapy on the neurological complications of Anderson Fabry disease. The 4th European round table on Fabry disease. Expectations of enzyme replacement therapy, Oct 17–18, 2003, Munich, Germany

    Google Scholar 

  29. Yamadera M, Yokoe M, Beck G et al (2009) Amelioration of white-matter lesions in a patient with Fabry disease. J Neurol Sci 279(1–2):118–120

    Article  PubMed  CAS  Google Scholar 

  30. Callegaro D, Kaimen-Maciel DR (2006) Fabry disease as a differential diagnosis of MS. Int MS J 13(1):27–30

    PubMed  CAS  Google Scholar 

  31. Saip S, Uluduz D, Erkol G (2007) Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg 109(4):361–363

    Article  PubMed  Google Scholar 

  32. Invernizzi P, Bonometti MA, Turri E et al (2008) A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler 14(7):1003–1006

    Article  PubMed  CAS  Google Scholar 

  33. Keilmann A, Hajioff D, Ramaswami U, on behalf of the FOS Investigators (2009) Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 32(6):739–744

    Article  PubMed  CAS  Google Scholar 

  34. Palla A, Hegemann S, Widmer U et al (2007) Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 254(10):1433–1442

    Article  PubMed  CAS  Google Scholar 

  35. Ries M, Kim HJ, Zalewski CK et al (2007) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130(Pt 1):143–150

    PubMed  CAS  Google Scholar 

  36. Hajioff D, Enever Y, Quiney R et al (2003) Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26(8):787–794

    Article  PubMed  CAS  Google Scholar 

  37. Torvin Møller A, Winther Bach F, Feldt-Rasmussen U et al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145(1–2):237–245

    Article  PubMed  Google Scholar 

  38. Rodrigues LG, Ferraz MJ, Rodrigues D et al (2009) Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 33(1):48–56

    Article  PubMed  CAS  Google Scholar 

  39. Maag R, Binder A, Maier C et al (2008) Detection of a characteristic painful neuropathy in Fabry disease: a pilot study. Pain Med 9(8):1217–1223

    Article  PubMed  Google Scholar 

  40. Laaksonen SM, Röyttä M, Jääskeläinen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119(6):1365–1372

    Article  PubMed  Google Scholar 

  41. Hoffmann B, Beck M, Sunder-Plassmann G et al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23(6):535–542

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Faculty, Albrecht-Kossel-Institute for Neuroregeneration, University of Rostock, Rostock, Germany

    Arndt Rolfs, Jan Lukas & Tobias Böttcher

  2. Department of Neurology, University of Rostock, Rostock, Germany

    Ales Dudesek

Authors
  1. Arndt Rolfs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ales Dudesek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Lukas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tobias Böttcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arndt Rolfs .

Editor information

Editors and Affiliations

  1. , Shaare Zedek Medical Center, Gaucher Clinic, Bayit Street 12, Jerusalem, 91034, Israel

    Deborah Elstein

  2. , Shaare Zedek Medical Center, Genetics Unit, Bayit Street 12, Jerusalem, 91031, Israel

    Gheona Altarescu

  3. University of Mainz, Children's Hospital, Langenbeckstrasse 1, Mainz, 55131, Germany

    Michael Beck

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Netherlands

About this chapter

Cite this chapter

Rolfs, A., Dudesek, A., Lukas, J., Böttcher, T. (2010). Neurological Manifestations in Fabry Disease. In: Elstein, D., Altarescu, G., Beck, M. (eds) Fabry Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9033-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9033-1_13

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9032-4

  • Online ISBN: 978-90-481-9033-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation